ROMAS study: An intestinal microbiome intervention affects biochemical disease activity in patients with antiphospholipid syndrome
Published: 29 December 2022| Version 1 | DOI: 10.17632/zxsjyjfzjd.1
Contributors:
Valérie Jansen, thijs van mensDescription
Aim of this study was to evaluate whether the gut microbiome affects disease activity in human APS. 15 APS patients with stable disease received oral vancomycin, 500mg four times daily for seven days. Disease activity was assessed at four time points by measuring a panel of clinical phenotype-related biomarkers: antiphospholipid antibodies (APLAs), complement and inflammation markers and hemostatic parameters. The primary outcome was change from baseline in the composite of the biomarker panel determined by multi-level principal component analysis.
Files
Institutions
Amsterdam UMC Locatie AMC Divisie 1
Categories
Gut Microbiome, Antiphospholipid Syndromes
Funding
Hartstichting
2020T013
Amsterdam University Medical Centers
Out of the Box grant of Amsterdam Reproduction & Development